/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

K

Ken Kato

Kurume University(JP)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

833

Papers

29.6K

Citations

75

h-index

310

i10-index

Ken Kato is an academic researcher from Kurume University. The author has contributed to research in topics: Esophageal Cancer Research and Treatment & Gastric Cancer Management and Outcomes & Cancer Immunotherapy and Biomarkers. The author has an h-index of 75, co-authored 709 publications.

ORCID: 0000-0002-1733-5072

Research Topics

Esophageal Cancer Research and Treatment Gastric Cancer Management and Outcomes Cancer Immunotherapy and Biomarkers Colorectal Cancer Treatments and Studies Esophageal and GI Pathology

Papers by this author

works

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

2021 · The Lancet · 1,479 citations

https://doi.org/10.1016/s0140-6736(21)01234-4

Jong‐Mu Sun Lin Shen Manish A. Shah Peter C. Enzinger

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

2019 · The Lancet Oncology · 1,196 citations

https://doi.org/10.1016/s1470-2045(19)30626-6

Ken Kato Byoung Chul Cho Masanobu Takahashi Morihito Okada

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

2020 · Journal of Clinical Oncology · 1,151 citations

https://doi.org/10.1200/jco.20.01888

Takashi Kojima Manish A. Shah Kei Muro Éric François

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

2022 · The Lancet Oncology · 712 citations

https://doi.org/10.1016/s1470-2045(21)00692-6

Yoon‐Koo Kang Li‐Tzong Chen Min‐Hee Ryu Do‐Youn Oh

Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2

2018 · Esophagus · 585 citations

https://doi.org/10.1007/s10388-018-0642-8

Yuko Kitagawa Takashi Uno Tsuneo Oyama Ken Kato

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

2017 · The Lancet Oncology · 379 citations

https://doi.org/10.1016/s1470-2045(17)30181-x

Toshihiro Kudo Yasuo Hamamoto Ken Kato Takashi Ura

Research topics

topics

Esophageal Cancer Research and Treatment

Gastric Cancer Management and Outcomes

Cancer Immunotherapy and Biomarkers

Colorectal Cancer Treatments and Studies

Esophageal and GI Pathology

Chat about Author

Papers

Chat

Click to start Chat